{"id":"NCT01914757","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist","officialTitle":"A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08","primaryCompletion":"2016-03","completion":"2016-03","firstPosted":"2013-08-02","resultsPosted":"2017-01-25","lastUpdate":"2017-01-25"},"enrollment":2508,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Benralizumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Benralizumab 30 mg q.4 weeks","type":"EXPERIMENTAL"},{"label":"Benralizumab 30 mg q.8 weeks","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether Benralizumab reduces the exacerbation rate in patients with a history of asthma exacerbations and uncontrolled asthma receiving ICS-LABA with or without oral corticosteroids and additional asthma controllers.","primaryOutcome":{"measure":"Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL","timeFrame":"Immediately following the first administration of study drug through Study Week 56.","effectByArm":[{"arm":"Benralizumab 30 mg q.4 Weeks","deltaMin":0.6,"sd":null},{"arm":"Benralizumab 30 mg q.8 Weeks","deltaMin":0.66,"sd":null},{"arm":"Placebo","deltaMin":0.93,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.002"},{"comp":"OG001 vs OG002","p":"0.019"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":215,"countries":["United States","Argentina","Canada","Chile","Germany","Japan","Philippines","Poland","Romania","Sweden","Ukraine"]},"refs":{"pmids":["35287231","32334141","31836949","31626906","30802500","30139780","30077185","29409951","29128192","27609406"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=1823&filename=d3250c00018_Revised_CSP_CALIMA..pdf"]},"adverseEventsSummary":{"seriousAny":{"events":46,"n":438},"commonTop":["Nasopharyngitis","Bronchitis","Asthma","Upper respiratory tract infection","Headache"]}}